Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 62175-270

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 62175-270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin Chloride Extended Release 1

Chemical structure of oxybutynin chloride, illustrating the arrangement of its molecular components including phenyl, cyclohexyl, ester linkage, alkyne group, amine, and hydrochloride moiety.*

FDA Label Image

Oxybutynin Chloride Extended Release 2

A line graph comparing the mean plasma R-Oxybutynin concentration (ng/mL) over 24 hours for oxybutynin chloride extended-release tablets 10 mg once daily (QD) versus oxybutynin 5 mg three times daily (TID). The X-axis represents time in hours, and the Y-axis shows concentration levels with error bars indicating variability.*

FDA Label Image

Oxybutynin Chloride Extended Release 3

A line graph depicting the mean plasma concentration of R-Oxybutynin (ng/mL) over time (hours). The graph shows data points with error bars at intervals from 0 to 24 hours, illustrating the plasma concentration trend following administration.*

FDA Label Image

Oxybutynin Chloride Extended Release 4

A horizontal line plot comparing mean change in episodes per week from baseline between oxybutynin chloride extended-release tablets and placebo. The x-axis represents mean change (±SD) ranging roughly from -40 to 40. Oxybutynin shows a negative mean change, indicating reduction, while placebo is closer to zero.*

FDA Label Image

Oxybutynin Chloride Extended Release 5

A bar chart comparing the mean change in episodes per week from baseline between oxybutynin chloride extended-release tablets and placebo. The horizontal axis represents the mean change with standard deviation, ranging from -40 to 40. The chart visually shows the difference in efficacy between the active drug and placebo groups.*

FDA Label Image

Oxybutynin Chloride Extended Release 6

A horizontal bar chart depicting the mean change (± standard deviation) in episodes per week from baseline for oxybutynin chloride extended-release tablets and oxybutynin alone. The x-axis represents the mean change ranging from -40 to 40 episodes per week, with the bars showing negative mean changes for both treatments, indicating a reduction in episodes.*

FDA Label Image

Oxybutynin Chloride Extended Release 7

Label for Oxybutynin Chloride Extended Release Tablets USP, 5 mg strength. The label states each tablet contains 5 mg oxybutynin chloride in an extended-release formulation. The package contains 100 tablets. It includes storage instructions at 25°C (77°F) with permitted excursions, and advises protection from moisture and humidity. Distributed by Lannett Company, Inc.*

FDA Label Image

Oxybutynin Chloride Extended Release 8

Label for Oxybutynin Chloride Extended-Release Tablets USP, 10 mg strength. The label states the active ingredient per tablet, the extended-release formulation, and storage instructions. It includes the quantity of 100 tablets and indicates prescription-only status. Distributed by Lannett Company, Inc., Philadelphia, PA.*

FDA Label Image

Oxybutynin Chloride Extended Release 9

Label for Oxybutynin Chloride Extended-Release Tablets USP, 15 mg strength. The label states each tablet contains 15 mg oxybutynin chloride in an extended-release formulation. It is distributed by Lannett Company, Inc., Philadelphia, PA, and packaged in a quantity of 100 tablets. Storage instructions and usage notes are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.